A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 446-449

  Kim, S J ^a   Kim, J S ^a   Kim, S C ^a   Kim, Y K ^a,a   Kang, J Y ^a   Yoon, H K ^a   Song, J S ^a   Lee, S H ^b   Moon, H S ^b   Kim, J W ^c   Kim, K H ^c   Kim, C H ^d   Shim, B Y ^d   Kim, H K ^d  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Uijeongbu St Mary's Hospital   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

Belotecan; Chemotherapy; Extensive stage disease; First line; Phase II study; Small cell lung cancer

Indexed keywords

BELOTECAN; CAMPTOTHECIN DERIVATIVE; ETOPOSIDE; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; DISEASE COURSE; INTRAVENOUS DRUG ADMINISTRATION; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; SMALL CELL LUNG CARCINOMA; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; TOPOISOMERASE I INHIBITORS;

EID: 77952548297     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.07.002     Document Type: Article

References (18)

1. Simon G.R., Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:324S-339S.
2. Crul M. CKD-602. Chong Kun Dang. Curr Opin Invest Drugs 2003, 4:1455-1459.
3. Lee J.H., Lee J.M., Kim J.K., Ahn S.K., Lee S.J., Kim M.Y., et al. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res 1998, 21:581-590.
4. Lee J.H., Lee J.M., Lim K.H., Kim J.K., Ahn S.K., Bang Y.J., et al. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann N Y Acad Sci 2000, 922:324-325.
5. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
6. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
7. Schiller J.H., Kim K., Hutson P., DeVore R., Glick J., Stewart J., et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996, 14:2345-2352.
8. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997, 15:2090-2096.
9. Negoro S., Fukuoka M., Niitani H., Suzuki A., Nakabayashi T., Kimura M., et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Gan To Kagaku Ryoho 1991, 18:1013-1019.
10. Rougier P., Bugat R., Douillard J.Y., Culine S., Suc E., Brunet P., et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997, 15:251-260.
11. Cunningham D., Pyrhonen S., James R.D., Punt C.J., Hickish T.F., Heikkila R., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413-1418.
12. Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407-1412.
13. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658-667.
14. Eckardt J.R., von Pawel J., Pujol J.L., Papai Z., Quoix E., Ardizzoni A., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007, 25:2086-2092.
15. Evans W.K., Shepherd F.A., Feld R., Osoba D., Dang P., Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985, 3:1471-1477.
16. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85-91.
17. Hanna N., Bunn P.A., Langer C., Einhorn L., Guthrie T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006, 24:2038-2043.
18. Lee D.H., Kim S.W., Suh C., Lee J.S., Lee J.H., Lee S.J., et al. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol 2008, 19:123-127.